Horizon Oncology Research, Inc. Participates in Phase II Clinical Study being Presented at ASH
December 5, 2013
Horizon Oncology Research, Inc. participates in the ProNAi Therapeutics Phase II Clinical Trial PNT2258 which will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana on December 8, 2013.
This clinical study presents promising data as the investigational drug PNT2258, a novel BCL2 inhibitor, is the first nucleic acid nanoparticle drug with Phase II data to be presented at a major cancer meeting of this kind.
To read the submitted abstract on the material to be presented, please use the following link: https://ash.confex.com/ash/2013/webprogram/Paper60684.html